Michael Bitzer

220 papers receiving 10k citations

Michael Bitzer's Hit Papers

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma 2024 · 239 citations
2390+5+11Years since publication2505007501k

Peers

Michael Bitzer
Comparison fields: 5 of 159
  • Hepatology 1.9k
  • Health Informatics 139
  • Oncology 1.2k
  • Cancer Research 491
  • Surgery 1.4k
Replace Nisar P. Malek with:
Nisar P. Malek Germany
Soo Young Park South Korea
Marco R. Novelli United Kingdom
Andrea Ruzzenente Italy
Nagy Adley Habib United Kingdom
Won Young Tak South Korea
Xiaolong Qi China
Jiahong Dong China
Su Pin Choo Singapore
Kunihito Gotoh Japan
Michael Bitzer relative to Nisar P. Malek Germany Nisar P. Malek's profile →
Citations per field
00.5×1.5×2.0×
Nisar P. Malek · 1×
Citations per year

Countries citing papers authored by Michael Bitzer

Since Specialization
Citations

This map shows the geographic impact of Michael Bitzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bitzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bitzer more than expected).

Fields of papers citing papers by Michael Bitzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bitzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bitzer. The network helps show where Michael Bitzer may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Bitzer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Bitzer Line = papers co-authored together Michael Bitzer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 242 papers — load more, or switch the sort, to bring in the rest.

#Work
1
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hit paper breakdown →
20211029
2
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
Hit paper breakdown →
2009737
3
Swarm Learning for decentralized and confidential clinical machine learning
Hit paper breakdown →
2021646
4
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Hit paper breakdown →
2021341
5
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Hit paper breakdown →
2023326
6 2005319
7
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Hit paper breakdown →
2024239
8
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
Hit paper breakdown →
2021230
9 2017206
10 2018197
11 2021195
12 2000183
13 2020170
14 2012162
15 1995160
16 2013150
17 2020124
18 2016120
19 2006105
20 2018101

About Michael Bitzer

Michael Bitzer is a scholar working on Hepatology, Genetics, Oncology, Cancer Research and Surgery, having authored 242 papers that have together received 10.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Virus-based gene therapy research (30 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers), Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (13 papers), COVID-19 Clinical Research Studies (10 papers), Meningioma and schwannoma management (9 papers) and Histone Deacetylase Inhibitors Research (7 papers). The work is most often cited by research in Hepatology (1.9k citations), Health Informatics (139 citations), Oncology (1.2k citations), Cancer Research (491 citations) and Surgery (1.4k citations). Michael Bitzer has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Ulrich M. Lauer, Sascha Venturelli, Sorin Armeanu, Wilfried Budach, M. Stahl, Michael Gregor, Helge Roland Topka, Hansjochen Wilke, Jorge Riera‐Knorrenschild and Martin Karl Walz. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Frontiers in Oncology, PLoS ONE and RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact